Compare Pfizer Inc (PFE) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs T-Mobile Us Inc — how do they compare? Pfizer Inc trades at $24.89 (market cap $142.14B), while T-Mobile Us Inc trades at $191 (market cap $206.45B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | TMUS | |
|---|---|---|
Market Cap | $142.14B | $206.45B |
Volume | 29,869,932 | — |
Sector | Health | Media |
52-Week High | $28.56 | $259.01 |
52-Week Low | $23.29 | $167.65 |
Enterprise Value | $192.80B | $324.15B |
Dividend Yield | 6.9% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
T-Mobile (TMUS) trades at $190.64, down 0.93% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings near 85. The company demonstrates robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion, though profit margins have moderated from 13.92% in 2024 to 12.44% in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending.
T-Mobile presents a compelling growth story in telecom with strong analyst support (83% buy ratings) and a $237.40 consensus price target implying 25% upside. Key risks include increasing debt-to-asset ratios (39.35% in 2025) and competitive pressures from satellite internet providers. The stock's current valuation at 20.79 P/E appears reasonable given growth prospects, though investors should monitor execution on subscriber and broadband growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
